Cabotegravir

Chemical formula: C₁₉H₁₇F₂N₃O₅ Molecular mass: 405.358 g/mol PubChem compound: 54713659

Therapeutic indications

Cabotegravir is indicated for:

Human Immunodeficiency Virus type 1 (HIV-1) infection

Population group: only adults (18 years old or older)

Cabotegravir tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:

oral lead in to assess tolerability of cabotegravir and rilpivirine prior to administration of long acting cabotegravir injection plus long acting rilpivirine injection.
oral therapy for adults who will miss planned dosing with cabotegravir injection plus rilpivirine injection.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

30 mg once daily

600 mg once at month 1 and thereafter 400-600 mg once every 1-2 months

Contraindications

Cabotegravir is contraindicated in the following cases:

Rifampicin, rifapentine, carbamazepine, oxcarbazepine, phenytoin, phenobarbital

at least one of

Rifampicin
Rifapentine
Carbamazepine
Oxcarbazepine
Phenytoin
Phenobarbital

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.